Heung-Woo Park1, Amber Dahlin2, Szeman Tse2, Qing Ling Duan2, Brooke Schuemann2, Fernando D Martinez3, Stephen P Peters4, Stanley J Szefler5, John J Lima6, Michiaki Kubo7, Mayumi Tamari7, Kelan G Tantisira8. 1. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. 2. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. 3. Arizona Respiratory Center, University of Arizona, College of Medicine, Tucson, Ariz. 4. Center for Genomics and Personalized Medicine Research and the Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC. 5. Department of Pediatric and Pharmacology, National Jewish Health and University of Colorado, Denver School of Medicine, Denver, Colo. 6. Center for Pharmacogenomics and Translational Research, Nemours Children's Clinic, Jacksonville, Fla. 7. Center for Integrative Medical Sciences, RIKEN, Kanagawa, Japan. 8. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Mass. Electronic address: kelan.tantisira@channing.harvard.edu.
Abstract
BACKGROUND: To date, genome-wide association studies (GWASs) of inhaled corticosteroid (ICS) response in asthmatic patients have focused primarily on lung function and exacerbations. OBJECTIVE: We hypothesized that GWAS analysis could identify novel genetic markers predicting a symptomatic response to ICSs. METHODS: We analyzed differences in asthma symptoms in response to ICSs in 124 white children from the Childhood Asthma Management Program (CAMP) trial using scores from diary cards. Of the 440,862 single nucleotide polymorphisms (SNPs) analyzed, the top 100 ranked SNPs were pursued for replication initially in subjects from the pediatric Childhood Asthma Research and Education trials (77 white children) and then in subjects from the adult Asthma Clinical Research Network (110 white adults) and Leukotriene Modifier or Corticosteroid or Corticosteroid-Salmeterol trials (110 white adults). RESULTS: The lowest P value for GWAS analysis in the CAMP trial was 8.94 × 10(-8) (rs2388639). Of the 60 SNPs available in the Childhood Asthma Research and Education Network trials, rs1558726 (combined P = 1.02 × 10(-5)), rs2388639 (combined P = 8.56 × 10(-9)), and rs10044254 (combined P = 9.16 × 10(-8)) independently replicated. However, these 3 SNPs were not additionally replicated in the adult asthmatic patients of the remaining trials. rs10044254 lies in the intronic region of F-box and leucine-rich repeat protein 7 (FBXL7) and is associated with decreased expression in immortalized B cells derived from CAMP participants. CONCLUSIONS: We have identified a novel SNP, rs10044254, associated with both decreased expression of FBXL7 and improved symptomatic response to ICSs in 2 independent pediatric cohorts. Our results suggest that there might be a specific genetic mechanism regulating symptomatic response to ICSs in children that does not carry over to adults.
BACKGROUND: To date, genome-wide association studies (GWASs) of inhaled corticosteroid (ICS) response in asthmatic patients have focused primarily on lung function and exacerbations. OBJECTIVE: We hypothesized that GWAS analysis could identify novel genetic markers predicting a symptomatic response to ICSs. METHODS: We analyzed differences in asthma symptoms in response to ICSs in 124 white children from the Childhood Asthma Management Program (CAMP) trial using scores from diary cards. Of the 440,862 single nucleotide polymorphisms (SNPs) analyzed, the top 100 ranked SNPs were pursued for replication initially in subjects from the pediatric Childhood Asthma Research and Education trials (77 white children) and then in subjects from the adult Asthma Clinical Research Network (110 white adults) and Leukotriene Modifier or Corticosteroid or Corticosteroid-Salmeterol trials (110 white adults). RESULTS: The lowest P value for GWAS analysis in the CAMP trial was 8.94 × 10(-8) (rs2388639). Of the 60 SNPs available in the Childhood Asthma Research and Education Network trials, rs1558726 (combined P = 1.02 × 10(-5)), rs2388639 (combined P = 8.56 × 10(-9)), and rs10044254 (combined P = 9.16 × 10(-8)) independently replicated. However, these 3 SNPs were not additionally replicated in the adult asthmatic patients of the remaining trials. rs10044254 lies in the intronic region of F-box and leucine-rich repeat protein 7 (FBXL7) and is associated with decreased expression in immortalized B cells derived from CAMPparticipants. CONCLUSIONS: We have identified a novel SNP, rs10044254, associated with both decreased expression of FBXL7 and improved symptomatic response to ICSs in 2 independent pediatric cohorts. Our results suggest that there might be a specific genetic mechanism regulating symptomatic response to ICSs in children that does not carry over to adults.
Authors: Matthew W Foster; J Will Thompson; Michael T Forrester; Yonggang Sha; Timothy J McMahon; Dawn E Bowles; M Arthur Moseley; Harvey E Marshall Journal: Nitric Oxide Date: 2013-02-21 Impact factor: 4.427
Authors: Anne L Fuhlbrigge; Robert J Adams; Theresa W Guilbert; Evie Grant; Paula Lozano; Susan L Janson; Fernando Martinez; Kevin B Weiss; Scott T Weiss Journal: Am J Respir Crit Care Med Date: 2002-10-15 Impact factor: 21.405
Authors: Stanley J Szefler; Brenda R Phillips; Fernando D Martinez; Vernon M Chinchilli; Robert F Lemanske; Robert C Strunk; Robert S Zeiger; Gary Larsen; Joseph D Spahn; Leonard B Bacharier; Gordon R Bloomberg; Theresa W Guilbert; Gregory Heldt; Wayne J Morgan; Mark H Moss; Christine A Sorkness; Lynn M Taussig Journal: J Allergy Clin Immunol Date: 2005-02 Impact factor: 10.793
Authors: Jill S Halterman; Kenneth M McConnochie; Kelly M Conn; H Lorrie Yoos; Jeffrey M Kaczorowski; Robert J Holzhauer; Marjorie Allan; Peter G Szilagyi Journal: Ambul Pediatr Date: 2003 Mar-Apr
Authors: Stephen P Peters; Nicholas Anthonisen; Mario Castro; Janet T Holbrook; Charles G Irvin; Lewis J Smith; Robert A Wise Journal: N Engl J Med Date: 2007-05-17 Impact factor: 91.245
Authors: Gregory A Hawkins; Ross Lazarus; Richard S Smith; Kelan G Tantisira; Deborah A Meyers; Stephen P Peters; Scott T Weiss; Eugene R Bleecker Journal: J Allergy Clin Immunol Date: 2009-02-28 Impact factor: 10.793
Authors: Niloufar Farzan; Susanne J Vijverberg; Anand K Andiappan; Lambang Arianto; Vojko Berce; Natalia Blanca-López; Hans Bisgaard; Klaus Bønnelykke; Esteban G Burchard; Paloma Campo; Glorisa Canino; Bruce Carleton; Juan C Celedón; Fook Tim Chew; Wen Chin Chiang; Michelle M Cloutier; Denis Daley; Herman T Den Dekker; F Nicole Dijk; Liesbeth Duijts; Carlos Flores; Erick Forno; Daniel B Hawcutt; Natalia Hernandez-Pacheco; Johan C de Jongste; Michael Kabesch; Gerard H Koppelman; Vangelis G Manolopoulos; Erik Melén; Somnath Mukhopadhyay; Sara Nilsson; Colin N Palmer; Maria Pino-Yanes; Munir Pirmohamed; Uros Potočnik; Jan A Raaijmakers; Katja Repnik; Maximilian Schieck; Yang Yie Sio; Rosalind L Smyth; Csaba Szalai; Kelan G Tantisira; Steve Turner; Marc P van der Schee; Katia M Verhamme; Anke H Maitland-van der Zee Journal: Pharmacogenomics Date: 2017-06-22 Impact factor: 2.533
Authors: Natalia Hernandez-Pacheco; Niloufar Farzan; Ben Francis; Leila Karimi; Katja Repnik; Susanne J Vijverberg; Patricia Soares; Maximilian Schieck; Mario Gorenjak; Erick Forno; Celeste Eng; Sam S Oh; Lina Pérez-Méndez; Vojko Berce; Roger Tavendale; Lesly-Anne Samedy; Scott Hunstman; Donglei Hu; Kelley Meade; Harold J Farber; Pedro C Avila; Denise Serebrisky; Shannon M Thyne; Emerita Brigino-Buenaventura; William Rodriguez-Cintron; Saunak Sen; Rajesh Kumar; Michael Lenoir; Jose R Rodriguez-Santana; Juan C Celedón; Somnath Mukhopadhyay; Uroš Potočnik; Munir Pirmohamed; Katia M Verhamme; Michael Kabesch; Colin N A Palmer; Daniel B Hawcutt; Carlos Flores; Anke H Maitland-van der Zee; Esteban G Burchard; Maria Pino-Yanes Journal: Clin Exp Allergy Date: 2019-02-15 Impact factor: 5.018
Authors: Anne M Fitzpatrick; Susan T Stephenson; Milton R Brown; Khristopher Nguyen; Shaneka Douglas; Lou Ann S Brown Journal: J Allergy Clin Immunol Pract Date: 2016-09-21
Authors: Cancan Qi; Yale Jiang; Ivana V Yang; Erick Forno; Ting Wang; Judith M Vonk; Ulrike Gehring; Henriëtte A Smit; Edith B Milanzi; Orestes A Carpaij; Marijn Berg; Laura Hesse; Sharon Brouwer; Jonathan Cardwell; Cornelis J Vermeulen; Edna Acosta-Pérez; Glorisa Canino; Nadia Boutaoui; Maarten van den Berge; Sarah A Teichmann; Martijn C Nawijn; Wei Chen; Juan C Celedón; Cheng-Jian Xu; Gerard H Koppelman Journal: J Allergy Clin Immunol Date: 2020-01-14 Impact factor: 10.793
Authors: Albert M Levin; Hongsheng Gui; Natalia Hernandez-Pacheco; Mao Yang; Shujie Xiao; James J Yang; Samantha Hochstadt; Andrea J Barczak; Walter L Eckalbar; Dean Rynkowski; Lesly-Anne Samedy; Pui-Yan Kwok; Maria Pino-Yanes; David J Erle; David E Lanfear; Esteban G Burchard; L Keoki Williams Journal: J Allergy Clin Immunol Date: 2018-10-24 Impact factor: 10.793
Authors: Michael J McGeachie; Ann C Wu; Sze Man Tse; George L Clemmer; Joanne Sordillo; Blanca E Himes; Jessica Lasky-Su; Robert P Chase; Fernando D Martinez; Peter Weeke; Christian M Shaffer; Hua Xu; Josh C Denny; Dan M Roden; Reynold A Panettieri; Benjamin A Raby; Scott T Weiss; Kelan G Tantisira Journal: J Allergy Clin Immunol Date: 2015-06-12 Impact factor: 10.793